Cargando…

Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics

Introduction: The aim of the present study was to establish a simple method for the determination of riluzole in human plasma by ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and apply it for the determination of riluzole in amyotrophic lateral sclerosis (ALS) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhuo, Liu, Xin, Zuo, Wei, Fu, Qiang, Xu, Tingting, Cui, Liying, Zhang, Bo, Peng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445645/
https://www.ncbi.nlm.nih.gov/pubmed/37621312
http://dx.doi.org/10.3389/fphar.2023.1227354
_version_ 1785094219261542400
author Sun, Zhuo
Liu, Xin
Zuo, Wei
Fu, Qiang
Xu, Tingting
Cui, Liying
Zhang, Bo
Peng, Ying
author_facet Sun, Zhuo
Liu, Xin
Zuo, Wei
Fu, Qiang
Xu, Tingting
Cui, Liying
Zhang, Bo
Peng, Ying
author_sort Sun, Zhuo
collection PubMed
description Introduction: The aim of the present study was to establish a simple method for the determination of riluzole in human plasma by ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and apply it for the determination of riluzole in amyotrophic lateral sclerosis (ALS) patients. Methods: Samples were prepared by protein precipitation and were then gradient-eluted on a column of ACQUITY UPLC(®) HSS T3 by using 0.1% formic acid acetonitrile and 0.1% formic acid water as the mobile phase. Detection was performed on a Xevo TQ-S tandem mass spectrometer in the multiple-reaction monitoring mode using positive electrospray ionization. Validation was performed in the range of 5–800 ng/mL. Results and discussion: Three batches of precision accuracy, selectivity, matrix effects, extraction recovery, and stability were also verified and met the requirements. The results showed that the method was reliable and successfully applied to the pharmacokinetics study of riluzole in Chinese amyotrophic lateral sclerosis patients. Meanwhile, in comparison with other prior published methods, our method has the advantages of simple sample preparation, relatively short running time, and small plasma sample consumption, which represented a high-throughput sample determination potential.
format Online
Article
Text
id pubmed-10445645
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104456452023-08-24 Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics Sun, Zhuo Liu, Xin Zuo, Wei Fu, Qiang Xu, Tingting Cui, Liying Zhang, Bo Peng, Ying Front Pharmacol Pharmacology Introduction: The aim of the present study was to establish a simple method for the determination of riluzole in human plasma by ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and apply it for the determination of riluzole in amyotrophic lateral sclerosis (ALS) patients. Methods: Samples were prepared by protein precipitation and were then gradient-eluted on a column of ACQUITY UPLC(®) HSS T3 by using 0.1% formic acid acetonitrile and 0.1% formic acid water as the mobile phase. Detection was performed on a Xevo TQ-S tandem mass spectrometer in the multiple-reaction monitoring mode using positive electrospray ionization. Validation was performed in the range of 5–800 ng/mL. Results and discussion: Three batches of precision accuracy, selectivity, matrix effects, extraction recovery, and stability were also verified and met the requirements. The results showed that the method was reliable and successfully applied to the pharmacokinetics study of riluzole in Chinese amyotrophic lateral sclerosis patients. Meanwhile, in comparison with other prior published methods, our method has the advantages of simple sample preparation, relatively short running time, and small plasma sample consumption, which represented a high-throughput sample determination potential. Frontiers Media S.A. 2023-08-09 /pmc/articles/PMC10445645/ /pubmed/37621312 http://dx.doi.org/10.3389/fphar.2023.1227354 Text en Copyright © 2023 Sun, Liu, Zuo, Fu, Xu, Cui, Zhang and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sun, Zhuo
Liu, Xin
Zuo, Wei
Fu, Qiang
Xu, Tingting
Cui, Liying
Zhang, Bo
Peng, Ying
Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title_full Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title_fullStr Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title_full_unstemmed Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title_short Development of a robust UPLC-MS/MS method for the quantification of riluzole in human plasma and its application in pharmacokinetics
title_sort development of a robust uplc-ms/ms method for the quantification of riluzole in human plasma and its application in pharmacokinetics
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445645/
https://www.ncbi.nlm.nih.gov/pubmed/37621312
http://dx.doi.org/10.3389/fphar.2023.1227354
work_keys_str_mv AT sunzhuo developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT liuxin developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT zuowei developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT fuqiang developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT xutingting developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT cuiliying developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT zhangbo developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics
AT pengying developmentofarobustuplcmsmsmethodforthequantificationofriluzoleinhumanplasmaanditsapplicationinpharmacokinetics